CN1172669C - 沙利度坦在制造治疗或预防主要抑郁性病症的药物中的应用 - Google Patents

沙利度坦在制造治疗或预防主要抑郁性病症的药物中的应用 Download PDF

Info

Publication number
CN1172669C
CN1172669C CNB008066817A CN00806681A CN1172669C CN 1172669 C CN1172669 C CN 1172669C CN B008066817 A CNB008066817 A CN B008066817A CN 00806681 A CN00806681 A CN 00806681A CN 1172669 C CN1172669 C CN 1172669C
Authority
CN
China
Prior art keywords
treatment
prevention
major depressive
manufacture
depressive disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008066817A
Other languages
English (en)
Chinese (zh)
Other versions
CN1348371A (zh
Inventor
X��������-������
X·埃蒙兹-阿尔特
P·索布里
R·斯坦伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of CN1348371A publication Critical patent/CN1348371A/zh
Application granted granted Critical
Publication of CN1172669C publication Critical patent/CN1172669C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CNB008066817A 1999-04-27 2000-04-25 沙利度坦在制造治疗或预防主要抑郁性病症的药物中的应用 Expired - Fee Related CN1172669C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/05338 1999-04-27
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Publications (2)

Publication Number Publication Date
CN1348371A CN1348371A (zh) 2002-05-08
CN1172669C true CN1172669C (zh) 2004-10-27

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008066817A Expired - Fee Related CN1172669C (zh) 1999-04-27 2000-04-25 沙利度坦在制造治疗或预防主要抑郁性病症的药物中的应用

Country Status (32)

Country Link
US (3) US6573281B1 (https=)
EP (1) EP1173179B1 (https=)
JP (1) JP2002542281A (https=)
KR (1) KR20020001850A (https=)
CN (1) CN1172669C (https=)
AR (1) AR023597A1 (https=)
AT (1) ATE234617T1 (https=)
AU (1) AU764304B2 (https=)
BG (1) BG65472B1 (https=)
BR (1) BR0010006A (https=)
CA (1) CA2370834C (https=)
CZ (1) CZ294904B6 (https=)
DE (1) DE60001725T2 (https=)
DK (1) DK1173179T3 (https=)
EE (1) EE05211B1 (https=)
ES (1) ES2193065T3 (https=)
FR (1) FR2792835B3 (https=)
HU (1) HUP0200969A3 (https=)
IL (1) IL145269A0 (https=)
MX (1) MXPA01010904A (https=)
NO (1) NO20015228L (https=)
NZ (1) NZ513851A (https=)
PL (1) PL196479B1 (https=)
PT (1) PT1173179E (https=)
RU (1) RU2238726C2 (https=)
SI (1) SI1173179T1 (https=)
SK (1) SK285459B6 (https=)
TR (1) TR200102512T2 (https=)
TW (1) TWI225399B (https=)
UA (1) UA69441C2 (https=)
WO (1) WO2000064423A2 (https=)
ZA (1) ZA200107143B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
EP1276729B1 (en) * 2000-04-06 2008-07-09 AstraZeneca AB New neurokinin antagonists for use as medicaments
DE60114597T2 (de) * 2000-04-06 2006-07-20 Astrazeneca Ab Naphthamid-neurokinin antagonisten zur verwendung als medikamente
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
MX2010002585A (es) * 2007-09-14 2010-03-26 Hoffmann La Roche Derivados de piperidina como antagonistas del receptor nk3.
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
HUP0200969A3 (en) 2004-03-01
PL351922A1 (en) 2003-06-30
ZA200107143B (en) 2002-10-30
FR2792835B3 (fr) 2001-05-25
DE60001725T2 (de) 2004-02-05
CZ294904B6 (cs) 2005-04-13
AU4303400A (en) 2000-11-10
TWI225399B (en) 2004-12-21
HUP0200969A2 (hu) 2002-07-29
PT1173179E (pt) 2003-06-30
IL145269A0 (en) 2002-06-30
US20030176462A1 (en) 2003-09-18
US6573281B1 (en) 2003-06-03
RU2238726C2 (ru) 2004-10-27
ES2193065T3 (es) 2003-11-01
EE200100553A (et) 2003-02-17
MXPA01010904A (es) 2002-06-21
TR200102512T2 (tr) 2002-04-22
NO20015228D0 (no) 2001-10-25
CN1348371A (zh) 2002-05-08
AU764304B2 (en) 2003-08-14
AR023597A1 (es) 2002-09-04
DE60001725D1 (de) 2003-04-24
US20080227818A1 (en) 2008-09-18
EP1173179A2 (fr) 2002-01-23
WO2000064423A3 (fr) 2001-04-19
BG65472B1 (bg) 2008-09-30
BR0010006A (pt) 2002-01-15
US7390823B2 (en) 2008-06-24
PL196479B1 (pl) 2008-01-31
JP2002542281A (ja) 2002-12-10
NZ513851A (en) 2003-04-29
CZ20013812A3 (cs) 2002-02-13
UA69441C2 (uk) 2004-09-15
CA2370834A1 (en) 2000-11-02
EE05211B1 (et) 2009-10-15
EP1173179B1 (fr) 2003-03-19
HK1041821A1 (en) 2002-07-26
SK15472001A3 (sk) 2002-03-05
ATE234617T1 (de) 2003-04-15
BG105962A (en) 2002-05-31
WO2000064423A2 (fr) 2000-11-02
DK1173179T3 (da) 2003-07-14
SK285459B6 (sk) 2007-02-01
KR20020001850A (ko) 2002-01-09
SI1173179T1 (en) 2003-06-30
NO20015228L (no) 2001-12-21
FR2792835A1 (fr) 2000-11-03
CA2370834C (en) 2007-09-25

Similar Documents

Publication Publication Date Title
JP5158919B2 (ja) 延長放出経口用量組成物
US20080227818A1 (en) Use of saredutant or its pharmaceutically acceptable salts in the treatment of mixed anxiety-depression disorders
KR100283709B1 (ko) 안정한 서방성 경구 투여 조성물
US6200958B1 (en) Agent for treating high-risk impaired glucose tolerance
HUT71222A (en) Pharmaceutical compositions for inhibiting pulmonary hypertenzive diseases containing 2-phenyl-3-aroyl-benzotiophene derivatives and process for their preparation
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
US7226614B2 (en) Tablet comprising cetirizine and pseudoephedrine
JP2005537221A (ja) トラマドールの徐放性製剤
AU706594B2 (en) Treatment of traumatic brain injury
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine
EP3297612B1 (en) Pharmaceutical composition comprising atomoxetine and method for the preparation thereof
HUP0402241A2 (hu) Metformin és 4-oxo-butánsav kombinációját tartalmazó gyógyászati készítmény, és a készítmény alkalmazása diabétesz kezelésére
JP2020528045A (ja) 非拍動性持続放出ベタヒスチン経口固形組成物
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
TW202604474A (zh) 奈必洛爾與氨氯地平組合物、其製備方法及用途
WO2025261504A1 (zh) 奈必洛尔与氨氯地平组合物、其制备方法及应用
HK1041821B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent major depressive disorders

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI - AVENTIS

Free format text: FORMER NAME OR ADDRESS: ST. SANOFI - SYNTHELABO CORPORATION

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: Paris France

Patentee before: Sanofi-Synthelabo

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041027

Termination date: 20120425